Canada’s Intellectual Property Firm

The Patented Medicine Prices Review Board (PMPRB) has released its 4th edition CompassRX report, Annual Public Drug Plan Expenditure Report for 2016/17. The report was prepared as part of the National Prescription Drug Utilization Information System (NPDUIS), and examines public drug plan expenditures in Canada, including analyzing the main factors that drive annual changes in prescription drug expenditures.

PMPRB has also released the 2017 Supplement to the Market Intelligence Report, Biologic Response Modifier Agents, 2015, both produced under the NPDUIS initiative. Using data from 2017, the Supplement provides updated information for market trends analyzed in the original report, which focuses on certain biologics that the report refers to as “biologic disease-modifying antirheumatic drugs or biologic DMARDs.”

Lastly, the PMPRB has released its 2017 Annual Report. The 2017 Annual Report includes a review of the PMPRB’s regulatory activities, analyses of sales and price trends of pharmaceuticals, as well as an overview of NPDUIS and analysis of research and development expenditures. On August 22, 2018, the Minister of Health tabled the 2017 Annual Report with the Clerks of the House of Commons and the Senate.